课题基金 / 基金详情

项目摘要

项目成果

Thomas J Kipps的其他基金

相关文献

中文摘要
翻译
项目总结(见说明): 我们检查了接受静脉输注自体白血病细胞的患者的反应。 体外转导表达重组CDI54(称为“Ad-CD154基因-Rx”)。我们发现了这样的 治疗可通过激活TAp7S,在缺乏功能性P53的非转导“旁观者”CLL细胞中诱导编码促凋亡蛋白的P53依赖基因。TAp7S的激活可以使这种耐药的CLL细胞对通常需要功能性p53的药物的细胞毒作用敏感。AD-CD154基因Rx还能诱导抗ROR1的自身抗体,这种抗体在正常成人组织中不存在,但在几乎所有病例的CLL细胞上都有表达,在发病机制中起着明显的作用。我们推测来那度胺对CLL患者的治疗可能与Ad-CDI54基因Rx的作用类似。我们还建议ROR1可以作为开发新疗法的一个很好的靶点。 最后,ROR1是参与CLL细胞与其微环境之间的串扰的几个因素的受体之一。在CLL微环境中发现的由护士样细胞(NLC)模拟的CLL细胞被诱导产生复杂的趋化因子(CCLS和CCL4),这些趋化因子可以将T细胞和NLC前体细胞招募到微环境中。初步数据表明,血清CCL3/CCL4水平可能作为疾病活动性的替代标记物,并可能作为对旨在诱导免疫激活或导致CLL微环境破坏的新疗法的早期反应,这些都是CRC正在调查的。为了利用这些观察结果,我们有以下特定的目的:1.评价来那度胺能否诱导抗ROR1自身抗体,并模拟Ad-CDI 54基因Rx增强耐药CLL细胞对化疗的敏感性的能力。确定这些效应是否主要发生在对来那度胺反应最好的患者身上;2.评估CCLS和CCL4的表达水平与疾病进展或对旨在诱导免疫激活或破坏CLL微环境的治疗策略的反应;3.评估以RORI疫苗、抗ROR1单抗、携带ROR1特异性嵌合抗原受体的T细胞或靶向ROR1的载药脂质体为靶点的策略。
英文摘要
PROJECT SUMMARY (See instructions): We examined the response of patients who received intravenous infusions of autologous leukemia cells transduced ex vivo to express a recombinant CDI 54 (termed "Ad-CD154 gene-Rx"). We found such treatment could induce p53-dependent genes encoding pro-apoptotic proteins in non-transduced "bystander" CLL cells that lacked functional p53 via c-abl-kinase activafion of TAp7S. Activation of TAp7S could sensitize such drug-resistant CLL cells to the cytotoxic effects of drugs that ordinarily require functional p53. Ad-CD154 gene Rx also could induce auto antibodies to ROR1, which found absent on normal adult tissues, but expressed on CLL cells of virtually all cases, where it plays an apparent role in pathogenesis. We hypothesize that treatment of CLL patients with lenalidomide might mimic these effects of Ad-CDI 54 gene Rx. We also propose that ROR1could serve as an excellent target for development of novel therapies. Finally, ROR1 is one of several receptors for factors engaged in the cross talk between CLL cells and its microenvironment. CLL cells simulated by nurse like cells (NLC) found in the CLL microenvironment are induced to elaborate chemokines (CCLS and CCL4) that can recruit T cells and NLC-precursor cells to the microenvironment. Preliminary data suggest that the serum levels of CCL3/CCL4 might serve as surrogate markers of disease activity and possibly of early response to novel therapies intended to induce immune activation or cause disruption of the CLL microenvironment that are being investigated by the CRC. To take advantage of these observations we have the following specific aims: 1. Evaluate whether lenalidomide can induce anti-ROR1 auto antibodies and mimic the capacity of Ad-CDI 54 Gene Rx to enhance sensitivity of drug-resistant CLL cells to chemotherapy. Determine whether such effects are noted primarily in patients who are most likely to respond favorably to lenalidomide; 2. Evaluate expression levels of CCLS and CCL4 in relation to disease progression or response to treatment strategies intended to induce immune activation or disrupt the CLL microenvironment; 3. Evaluate strategies to target RORI with RORI vaccines, anti-ROR1 mAbs, T cells bearing ROR1-specific chimeric antigen receptors, or drug-laden liposomes that target ROR1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Non-canonical Wnt-Receptor Signaling and Targeted Therapies
Non-canonical Wnt-Receptor Signaling and Targeted Therapies
Non-canonical Wnt-Receptor Signaling and Targeted Therapies
Non-canonical Wnt-Receptor Signaling and Targeted Therapies